Trial Search Results

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to find tumors in patients with prostate cancer who are undergoing resection surgery for prostate cancer that is prognostically expected to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET/MRI, may help find and diagnose prostate cancer, and reveal out how far the disease has spread. Radioactive drugs, such as 68Ga-PSMA-11, may bind to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Drug: 68Ga-PSMA-11
  • Procedure: Magnetic resonance imaging (MRI)
  • Procedure: Positron Emission Tomography (PET)


Phase 2/Phase 3



   - Biopsy-proven prostate adenocarcinoma

   - Planned prostatectomy with lymph node dissection

   - Intermediate- to high-risk disease (as determined by elevated prostate-specific
   antigen (PSA) [PSA > 10], T stage [T2b or greater], Gleason score [Gleason score > 6]
   or other risk factors)

   - Karnofsky performance status of ≥ 50 [or Eastern Cooperative Oncology Group
   (ECOG)/World Health Organization (WHO) equivalent]

   - Diagnostic CT or MRI performed within 90 days of the research PET

   - Able to provide written consent


   - Patients not capable of getting PET study due to weight, claustrophobia, or inability
   to lay still for the duration of the exam

   - Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy, including focal
   ablation techniques (HiFu)

   - Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging and

   - Metallic implants (contraindicated for MRI)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pranav Hegde
Not Recruiting